RS 09 |
Catalog No.GC50297
One-Click Copy Product Info
|
RS 09 is a synthetic peptide that can activate the TLR-4 signaling pathway. RS 09 can function as an adjuvant to enhance the immune response in BALB/c mice.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1449566-36-2
Sample solution is provided at 25 µL, 10mM.
RS 09 is a synthetic peptide that can activate the TLR-4 signaling pathway. RS 09 can function as an adjuvant to enhance the immune response in BALB/c mice[1].
In vitro, RS 09 (10µM; 30min) rescued the suppressed protein levels of TLR4, p-p65/p65, and p-IκBα/IκBα caused by ETS2 deficiency in the inflammatory cell model[2]. The TLR4 agonist RS 09 (5μg/ml; 24h) impaired the neuroprotective effects of corilagin on N2a cells[3]. RS 09 (60µM) intervention inhibited anti-inflammatory and pro-M2 polarizing effects of metformin, activating TLR4/NF-κB pathway[4].
In vivo, In BALB/c mice, when used in combination with the prostate cancer-specific antigen X-15, RS 09 (25µg; 28 days; s.c.) significantly increased the levels of X-15-specific antibodies[1].
References:
[1] Shanmugam A, Rajoria S, George AL, et al. Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants. PLoS One. 2012;7(2):e30839.
[2] Liu B, Yu J, Zhang J, et al. TLR4/NF-κB-mediated M1 macrophage polarization contributes to the promotive effects of ETS2 on ulcerative colitis. Eur J Med Res. 2025 Jul 24;30(1):668.
[3] Lei Y, Zhou J, Xu D, et al. Corilagin Attenuates Neuronal Apoptosis and Ferroptosis of Parkinson's Disease through Regulating the TLR4/Src/NOX2 Signaling Pathway. ACS Chem Neurosci. 2025 Mar 5;16(5):968-980.
[4] Shen W, Wang Q, Shen G, et al. Regulation of macrophage polarization by metformin through inhibition of TLR4/NF-κB pathway to improve pre-eclampsia. Placenta. 2025 Feb;160:89-99.
| Cell experiment [1]: | |
Cell lines | RAW264.7 cells |
Preparation Method | The sh-NC/sh-ETS2 lentivirus was transfected into mouse macrophage RAW264.7 cells for 48h to achieve stable silencing of ETS2. To induce M1 macrophage polarization and establish an inflammatory cell model, the cells were stimulated with lipopolysaccharide (LPS) and interferon-γ (IFN-γ) for 12h. Subsequently, the TLR4 agonist RS 09 (10µM) was added to the cells for 30min to activate the TLR4/NF-κB signaling pathway. The RAW264.7 cells were then collected and resuspended in PBS. Next, 3µL of PE-conjugated iNOS and FITC-conjugated F4/80 antibodies were added, and the cells were incubated in the dark for 20-30min. After another wash, the cells were resuspended in 200µL of PBS, and the proportion of the iNOS+/F4/80+ subgroup was monitored by flow cytometry. |
Reaction Conditions | 10µM; 30min |
Applications | RS 09 rescued the suppressed protein levels of TLR4, p-p65/p65, and p-IκBα/IκBα caused by ETS2 deficiency in the inflammatory cell model. |
| Animal experiment [2]: | |
Animal models | Eight-week-old male BALB/c mice |
Preparation Method | Eight-week-old male BALB/c mice were divided into four groups (three mice per group). The 15-mer peptide antigen (X-15 peptide) was conjugated to Keyhole Limpet Hemocyanin (KLH) and injected subcutaneously. All mice were vaccinated with 100µg of X-15 conjugated to KLH on day 0 and received a booster of 50µg of X-15 conjugated to KLH on day 14. The difference between the groups was the type of adjuvant used, which was either Alum, RS 01, or RS 09. Alum was added to X-15-KLH at a 1:1 (v:v) ratio, while both RS 01 and RS 09 were added at a concentration of 25µg. OVA peptide (an 8-mer peptide) served as a negative non-adjuvant peptide control and was also used at a concentration of 25µg. Blood was collected on days 0, 14, and 28. The serum collected was used to determine the presence of X-15-specific antibodies via ELISA. |
Dosage form | 25µg; 28 days; s.c. |
Applications | In BALB/c mice, when used in combination with the prostate cancer-specific antigen X-15, RS 09 significantly increased the levels of X-15-specific antibodies. |
References: | |
| Cas No. | 1449566-36-2 | SDF | |
| Canonical SMILES | [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O | ||
| Formula | C31H49N9O9 | M.Wt | 691.78 |
| Solubility | Water : 100 mg/mL (144.55 mM; Need ultrasonic) | Storage | Store at -20°C, Sealed, light and moisture resistant storage |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4455 mL | 7.2277 mL | 14.4555 mL |
| 5 mM | 289.1 μL | 1.4455 mL | 2.8911 mL |
| 10 mM | 144.6 μL | 722.8 μL | 1.4455 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)